Britain is currently holding its breath as regulators draw ever-closer to approving the Pfizer/ BioNTech vaccine.
The news comes after Health Secretary Matt Hancock on Friday, November 20, asked British regulators to start assessing the Pfizer BioNTech vaccine, as the company filed for emergency authorisation in the US.
Both the Pfizer/ BioNTech and Moderna are in competition to become to first COVID-19 jab to be implemented across Europe.
Pfizer/ BioNTech submitted their emergency application to the European Medicines Agency on Monday, November 30, while Moderna submitted their application just one day later, on Tuesday, December 1.
If all is successful, the Pfizer/ BioNTech will, therefore, be the first vaccine to be approved, as the European Medicines Agency aims to complete its evaluation of the vaccine by December 29, subject to the level data available. Meanwhile, reports suggest the Moderna vaccine will be approved on January 12, two weeks later.
Pfizer said their vaccine is 95 per cent effective in preventing Covid-19 and has passed its safety checks.
If the application is approved, first deliveries may begin within hours, and jabs may begin as soon as December 7.
The UK has also secured 2 million more doses of the US Moderna vaccine, which trials suggest is 95 per cent effective in preventing Covid-19.
This brings the total number of doses ordered from Moderna by the Government to seven million, with a further 100 million doses ordered from Oxford, and 40 million doses from Pfizer BioNTech. An overall total of 357 million doses from seven different developers havs been ordered by the Government.
The Oxford vaccine, developed with AstraZeneca, can prevent on average 70.4 per cent of people from getting Covid-19, according to new data from late-stage trials in Britain and Brazil.
AstraZeneca said they will immediately prepare a submission for regulatory authorities and seek an Emergency Use Listing from the World Health Organisation.
Almost 200 vaccines have been put into development since January, with at least 15 in human trials, and the UK has invested in three main jabs. Here’s what you need to know about each one.